Pfizer Inc. Technical Analysis – Pfizer Inc. Trading: 2021-12-17

 Pfizer Inc. Technical Analysis – Pfizer Inc. Trading: 2021-12-17

Pfizer Inc. Technical Analysis

Spread the love

Pfizer Inc. Technical Analysis Summary

 Buy Stop: Above 58.89

Stop Loss: Below 50.40

IndicatorSignal
RSISell
MACDBuy
MA(200)Buy
Donchian ChannelBuy
Parabolic SARBuy
FractalsNeutral

 

Pfizer Inc. Chart Analysis

Pfizer Inc. Technical Analysis

The technical analysis of the Pfizer stock price chart on daily timeframe shows #S-PFE,Daily is retracing up above the 200-day moving average MA(200) which is rising itself. RSI is in overbought zone. We believe the bullish momentum will continue after the price breaches above the upper boundary of Donchian channel at 58.89. This level can be used as an entry point for placing a pending order to buy. The stop loss can be placed below the fractal low at 50.40. After placing the order, the stop loss is to be moved every day to the next fractal low, following Parabolic signals. Thus, we are changing the expected profit/loss ratio to the breakeven point. If the price meets the stop loss level (50.40) without reaching the order (58.89), we recommend cancelling the order: the market has undergone internal changes which were not taken into account.

Fundamental Analysis of Stocks – Pfizer Inc.

Tests showed Pfizer booster protects against Omicron variant. Will the Pfizer stock price continue rebounding?

Tests showed Pfizer booster shot protects against Omicron variant. Pfizer and BioNTech are now working on a vaccine that could target Omicron. The booster dose resulted in a similar level of protection against omicron as the initial two-dose series does against the first iteration of the virus. And recently the Food and Drug Administration and Centers for Disease Control and Prevention authorized Pfizer’s Covid booster for all adults, allowing also a one-third sized dose of the original vaccine for children as young as 5. Pfizer stock jumped in August after the FDA fully approved its Covid shot for patients 16 years old and up. At the same time, Pfizer is working on a two-pill antiviral called Paxlovid that could treat mild-to-moderate Covid in unvaccinated patients. In terms of earnings, Pfizer sales jumped 134% to $24.09 billion in the third quarter. Analysts estimate sales will rise to $24.34 billion in the fourth quarter. Expectations of rising sales are bullish for company’s stock price.

Related post